Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Carprofen

Carprofen
Contact us for more batch information
Select Batch
Purity:99.65%
Resource Download

Carprofen

Catalog No. T1325Cas No. 53716-49-7
Carprofen (Ridamyl) is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
50 mg$36In Stock
100 mg$52In Stock
200 mg$75In Stock
500 mg$125In Stock
1 mL x 10 mM (in DMSO)$50In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Carprofen"

Product Introduction

Bioactivity
Description
Carprofen (Ridamyl) is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities.
In vitro
Administration of 4 mg/kg Carprofen significantly elevated peak plasma concentrations in dogs. Compared to buprenorphine, Carprofen treatment resulted in marginally superior analgesic effects with reduced sedative action in canines. Preoperative administration of Carprofen in dogs yielded lower pain scores than other groups, with marked effectiveness observed 2 hours post-extubation. Carprofen provided sustained analgesia for 18 hours in treated canines without adverse side effects and notably improved the speed of recovery in limping birds.
In vivo
Carprofen binds to human serum albumin (HSA) via fluorescence and equilibrium dialysis methods, with two sets of binding constants [K1=5.1 μM (fluorescence) and 3.7 μM (ED), K2=37 μM (fluorescence) and 13 μM (ED)]. It predominantly binds to site II, the benzodiazepine site, while site I, the Warfarin site, exhibits a lower affinity for Carprofen. The carboxyl group of Carprofen plays a significant role in its high-affinity binding with HSA. Additionally, Carprofen (S and R enantiomers) inhibits canine COX2 with an IC50 of 0.102 microM, primarily attributed to the S enantiomer (IC50, 0.0371 μM), which is approximately 200 times more potent than the R enantiomer (IC50, 5.97 microM).
AliasRidamyl, Imadyl, Rimadyl
Chemical Properties
Molecular Weight273.71
FormulaC15H12ClNO2
Cas No.53716-49-7
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 51 mg/mL (186.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 55 mg/mL (200.94 mM)
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
1 mM3.6535 mL18.2675 mL36.5350 mL182.6751 mL
5 mM0.7307 mL3.6535 mL7.3070 mL36.5350 mL
10 mM0.3654 mL1.8268 mL3.6535 mL18.2675 mL
20 mM0.1827 mL0.9134 mL1.8268 mL9.1338 mL
50 mM0.0731 mL0.3654 mL0.7307 mL3.6535 mL
100 mM0.0365 mL0.1827 mL0.3654 mL1.8268 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords